EP3589315A4 - Compositions et procédés pour induire des anticorps anti-vih-1 - Google Patents

Compositions et procédés pour induire des anticorps anti-vih-1 Download PDF

Info

Publication number
EP3589315A4
EP3589315A4 EP18760878.1A EP18760878A EP3589315A4 EP 3589315 A4 EP3589315 A4 EP 3589315A4 EP 18760878 A EP18760878 A EP 18760878A EP 3589315 A4 EP3589315 A4 EP 3589315A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
compositions
methods
inducing hiv
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18760878.1A
Other languages
German (de)
English (en)
Other versions
EP3589315A1 (fr
Inventor
Barton F. Haynes
Kevin O. SAUNDERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/020823 external-priority patent/WO2017152146A2/fr
Application filed by Duke University filed Critical Duke University
Publication of EP3589315A1 publication Critical patent/EP3589315A1/fr
Publication of EP3589315A4 publication Critical patent/EP3589315A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP18760878.1A 2017-03-03 2018-03-02 Compositions et procédés pour induire des anticorps anti-vih-1 Pending EP3589315A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2017/020823 WO2017152146A2 (fr) 2016-03-03 2017-03-03 Compositions et procédés pour induire des anticorps du vih-1
US201862624620P 2018-01-31 2018-01-31
PCT/US2018/020788 WO2018161049A1 (fr) 2017-03-03 2018-03-02 Compositions et procédés pour induire des anticorps anti-vih-1

Publications (2)

Publication Number Publication Date
EP3589315A1 EP3589315A1 (fr) 2020-01-08
EP3589315A4 true EP3589315A4 (fr) 2021-06-23

Family

ID=63371208

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18760878.1A Pending EP3589315A4 (fr) 2017-03-03 2018-03-02 Compositions et procédés pour induire des anticorps anti-vih-1

Country Status (3)

Country Link
EP (1) EP3589315A4 (fr)
CA (1) CA3055204A1 (fr)
WO (1) WO2018161049A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151801A1 (fr) 2016-03-01 2017-09-08 Duke University Compositions comprenant des enveloppes de vih pour induire des anticorps de lignée ch235
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
CA3039089A1 (fr) 2016-10-03 2018-04-12 Duke University Procedes d'identification d'immunogenes par ciblage de mutations improbables
US20210009640A1 (en) * 2018-03-02 2021-01-14 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
WO2020072162A1 (fr) * 2018-10-01 2020-04-09 Duke University Compositions comprenant des enveloppes de vih pour induire des anticorps contre le vih-1
AU2019393745A1 (en) 2018-12-04 2021-06-10 California Institute Of Technology HIV vaccine immunogens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043386A1 (fr) * 2012-09-12 2014-03-20 Duke University Anticorps du lignage clonal
WO2015153638A1 (fr) * 2014-03-31 2015-10-08 Duke University Compositions comprenant des enveloppes de ch848, et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127108A1 (fr) 2014-02-19 2015-08-27 Duke University Enveloppes du vih -1 trimères des compositions et leurs utilisations
EP3189067B1 (fr) 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Protéines de l'enveloppe du vih-1 et leur utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014043386A1 (fr) * 2012-09-12 2014-03-20 Duke University Anticorps du lignage clonal
WO2015153638A1 (fr) * 2014-03-31 2015-10-08 Duke University Compositions comprenant des enveloppes de ch848, et leurs utilisations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. P. WEST ET AL: "Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 30, 24 July 2012 (2012-07-24), pages E2083 - E2090, XP055166144, ISSN: 0027-8424, DOI: 10.1073/pnas.1208984109 *
FLORIAN KLEIN ET AL: "Somatic Mutations of the Immunoglobulin Framework Are Generally Required for Broad and Potent HIV-1 Neutralization", CELL, vol. 153, no. 1, 1 March 2013 (2013-03-01), pages 126 - 138, XP055119651, ISSN: 0092-8674, DOI: 10.1016/j.cell.2013.03.018 *
H. MOUQUET ET AL: "Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 109, no. 47, 30 October 2012 (2012-10-30), pages E3268 - E3277, XP055068116, ISSN: 0027-8424, DOI: 10.1073/pnas.1217207109 *
HUA-XIN LIAO ET AL: "Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus", NATURE, vol. 496, no. 7446, 3 April 2013 (2013-04-03), London, pages 469 - 476, XP055226788, ISSN: 0028-0836, DOI: 10.1038/nature12053 *
See also references of WO2018161049A1 *

Also Published As

Publication number Publication date
EP3589315A1 (fr) 2020-01-08
WO2018161049A8 (fr) 2018-10-04
CA3055204A1 (fr) 2018-09-07
WO2018161049A1 (fr) 2018-09-07

Similar Documents

Publication Publication Date Title
IL265844A (en) Anti-lag-3 antibodies and preparations
EP3589373A4 (fr) Compositions et méthodes pour immunothérapie
EP3723803A4 (fr) Anticorps anti-trem2 et méthodes associées
ZA201806576B (en) Antibodies, pharmaceutical compositions and methods
IL262176A (en) Anti-tim-3 antibodies and preparations
EP3515478A4 (fr) Anticorps pour siglec-15 et leurs méthodes d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3585433A4 (fr) Compositions thérapeutiques et méthodes associées pour la photoimmunothérapie
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3493827A4 (fr) Compositions et procédés pour immunothérapie
EP3600325A4 (fr) Nouvelles compositions et méthodes
EP3589315A4 (fr) Compositions et procédés pour induire des anticorps anti-vih-1
EP3491026A4 (fr) Anticorps humains, compositions pharmaceutiques et procédés
EP3503879A4 (fr) Compositions et procédés associés
EP3423091A4 (fr) Compositions et procédés pour induire des anticorps du vih-1
EP3635100A4 (fr) Compositions et procédés pour exprimer l'otoferline
EP3258925A4 (fr) Méthodes et compositions pour réduire la vidange gastrique
EP3341021A4 (fr) Anticorps anti-alk et leurs procédés d'utilisation
EP3773718A4 (fr) Compositions et procédés comprenant des anticorps anti-nrp2
EP3442543A4 (fr) Compositions et méthodes pour la neurogenèse
EP3294341A4 (fr) Compositions et procédés de production de conjugués d'anticorps
EP3436083A4 (fr) Nouvelles compositions et méthodes
EP3253389A4 (fr) Compositions d'apilimod et procédés d'utilisation correspondants
EP3706558A4 (fr) Compositions et procédés d'aquaculture
TWI799417B (zh) 生物製藥組成物及相關方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/18 20060101ALI20201216BHEP

Ipc: C07K 14/16 20060101ALI20201216BHEP

Ipc: A61K 39/12 20060101AFI20201216BHEP

Ipc: A61K 9/127 20060101ALI20201216BHEP

Ipc: C12Q 1/68 20180101ALI20201216BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0039210000

Ipc: A61K0039120000

A4 Supplementary search report drawn up and despatched

Effective date: 20210520

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101AFI20210514BHEP

Ipc: A61K 9/127 20060101ALI20210514BHEP

Ipc: C07K 14/16 20060101ALI20210514BHEP

Ipc: C12Q 1/68 20180101ALI20210514BHEP

Ipc: A61P 31/18 20060101ALI20210514BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230116

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231102